A citation-based method for searching scientific literature

Henning Zelba, Jens Bedke, Jörg Hennenlotter, Sven Mostböck, Markus Zettl, Thomas Zichner, Anoop Chandran, Arnulf Stenzl, Hans-Georg Rammensee, Cécile Gouttefangeas. Cancer Immunol Res 2019
Times Cited: 33







List of co-cited articles
516 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K Choueiri, Elizabeth R Plimack, Philippe Barthélémy, Camillo Porta, Saby George,[...]. N Engl J Med 2018
39

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Robert Hawkins, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar,[...]. N Engl J Med 2019
36

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, Jaishree Bankoti, Mark Selby, Christopher J Nirschl, Matthew L Bettini, David M Gravano, Peter Vogel, Chih Long Liu,[...]. Cancer Res 2012
926
33

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Robert J Motzer, Konstantin Penkov, John Haanen, Brian Rini, Laurence Albiges, Matthew T Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Negrier, Motohide Uemura,[...]. N Engl J Med 2019
30

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J Korman,[...]. J Clin Invest 2015
416
27

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, Jenna M Sullivan, Bruce R Blazar, Vijay K Kuchroo, Ana C Anderson. J Exp Med 2010
27

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Julien Fourcade, Zhaojun Sun, Mourad Benallaoua, Philippe Guillaume, Immanuel F Luescher, Cindy Sander, John M Kirkwood, Vijay Kuchroo, Hassane M Zarour. J Exp Med 2010
867
27


The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Xin Yu, Kristin Harden, Lino C Gonzalez, Michelle Francesco, Eugene Chiang, Bryan Irving, Irene Tom, Sinisa Ivelja, Canio J Refino, Hilary Clark,[...]. Nat Immunol 2009
707
24

TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, Shin-Foong Ngiow, Nicole Joller, Dewar J Tan, Michele W L Teng, Mark J Smyth, Vijay K Kuchroo, Ana C Anderson. J Clin Invest 2015
312
24

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack,[...]. N Engl J Med 2015
24

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Grit S Herter-Sprie, Kevin A Buczkowski, William G Richards, Leena Gandhi, Amanda J Redig, Scott J Rodig, Hajime Asahina,[...]. Nat Commun 2016
839
21

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Nicolas A Giraldo, Etienne Becht, Yann Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sanchez-Salas, Alexandre Ingels, Stephane Oudard, Audrey Moatti,[...]. Clin Cancer Res 2017
173
21

TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer.
Kaori Sakuishi, Shin Foong Ngiow, Jenna M Sullivan, Michele W L Teng, Vijay K Kuchroo, Mark J Smyth, Ana C Anderson. Oncoimmunology 2013
201
18

Tim-3 and its role in regulating anti-tumor immunity.
Madhumita Das, Chen Zhu, Vijay K Kuchroo. Immunol Rev 2017
363
18

Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma.
Clémence Granier, Charles Dariane, Pierre Combe, Virginie Verkarre, Saïk Urien, Cécile Badoual, Hélène Roussel, Marion Mandavit, Patrice Ravel, Mathilde Sibony,[...]. Cancer Res 2017
117
18

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, Alexandria P Cogdill, Yang Zhao, Nana-Ama A S Anang, Miles C Andrews, Padmanee Sharma, Jing Wang, Jennifer A Wargo, Dana Pe'er,[...]. Cell 2017
655
18

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
David F McDermott, Mahrukh A Huseni, Michael B Atkins, Robert J Motzer, Brian I Rini, Bernard Escudier, Lawrence Fong, Richard W Joseph, Sumanta K Pal, James A Reeves,[...]. Nat Med 2018
581
18

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
18

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Lawrence Fong, Andrew Hotson, John D Powderly, Mario Sznol, Rebecca S Heist, Toni K Choueiri, Saby George, Brett G M Hughes, Matthew D Hellmann, Dale R Shepard,[...]. Cancer Discov 2020
110
18

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Junko Matsuzaki, Sacha Gnjatic, Paulette Mhawech-Fauceglia, Amy Beck, Austin Miller, Takemasa Tsuji, Cheryl Eppolito, Feng Qian, Shashikant Lele, Protul Shrikant,[...]. Proc Natl Acad Sci U S A 2010
562
18

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
Nicolas A Giraldo, Etienne Becht, Franck Pagès, Georgios Skliris, Virginie Verkarre, Yann Vano, Arnaud Mejean, Nicolas Saint-Aubert, Laetitia Lacroix, Ivo Natario,[...]. Clin Cancer Res 2015
241
18

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Georgina V Long, Reinhard Dummer, Omid Hamid, Thomas F Gajewski, Christian Caglevic, Stephane Dalle, Ana Arance, Matteo S Carlino, Jean-Jacques Grob, Tae Min Kim,[...]. Lancet Oncol 2019
387
18

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Christopher J Ricketts, Aguirre A De Cubas, Huihui Fan, Christof C Smith, Martin Lang, Ed Reznik, Reanne Bowlby, Ewan A Gibb, Rehan Akbani, Rameen Beroukhim,[...]. Cell Rep 2018
302
18

Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, Catherine J Wu, Gad Getz, Nir Hacohen. Cell 2015
18

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
18

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy.
Long Long, Xue Zhang, Fuchun Chen, Qi Pan, Pronnaphat Phiphatwatchara, Yuyang Zeng, Honglei Chen. Genes Cancer 2018
155
15

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.
Ila Datar, Miguel F Sanmamed, Jun Wang, Brian S Henick, Jungmin Choi, Ti Badri, Weilai Dong, Nikita Mani, Maria Toki, Luis D Mejías,[...]. Clin Cancer Res 2019
112
15

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
15

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J Johnston, Laetitia Comps-Agrar, Jason Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Summer Park, Vincent Javinal, Henry Chiu, Bryan Irving,[...]. Cancer Cell 2014
564
15

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Xin Gao, Yibei Zhu, Gang Li, Haitao Huang, Guangbo Zhang, Fengming Wang, Jing Sun, Qianting Yang, Xueguang Zhang, Binfeng Lu. PLoS One 2012
240
15

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
Loise M Francisco, Victor H Salinas, Keturah E Brown, Vijay K Vanguri, Gordon J Freeman, Vijay K Kuchroo, Arlene H Sharpe. J Exp Med 2009
15

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
15

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Yasin Şenbabaoğlu, Ron S Gejman, Andrew G Winer, Ming Liu, Eliezer M Van Allen, Guillermo de Velasco, Diana Miao, Irina Ostrovnaya, Esther Drill, Augustin Luna,[...]. Genome Biol 2016
406
15

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Anthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, Kyriakos P Papadopoulos, Amita Patnaik, Drew W Rasco, Donna Di Gravio, Bo Huang, Dhiraj Gambhire, Ying Chen,[...]. Clin Cancer Res 2017
136
15

Tim-3 finds its place in the cancer immunotherapy landscape.
Nandini Acharya, Catherine Sabatos-Peyton, Ana Carrizosa Anderson. J Immunother Cancer 2020
102
15


Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Brian I Rini, Thomas Powles, Michael B Atkins, Bernard Escudier, David F McDermott, Cristina Suarez, Sergio Bracarda, Walter M Stadler, Frede Donskov, Jae Lyun Lee,[...]. Lancet 2019
505
15

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
379
15

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Alice L Hung, Russell Maxwell, Debebe Theodros, Zineb Belcaid, Dimitrios Mathios, Andrew S Luksik, Eileen Kim, Adela Wu, Yuanxuan Xia, Tomas Garzon-Muvdi,[...]. Oncoimmunology 2018
142
12

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Jun Wang, Miguel F Sanmamed, Ila Datar, Tina Tianjiao Su, Lan Ji, Jingwei Sun, Ling Chen, Yusheng Chen, Gefeng Zhu, Weiwei Yin,[...]. Cell 2019
312
12

CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, Paz Prieto-Martin, Tomoyuki Yamaguchi, Makoto Miyara, Zoltan Fehervari, Takashi Nomura, Shimon Sakaguchi. Science 2008
12

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu-Lieskovan, Davis Y Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly,[...]. N Engl J Med 2016
12

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
Daniela S Thommen, Viktor H Koelzer, Petra Herzig, Andreas Roller, Marcel Trefny, Sarah Dimeloe, Anna Kiialainen, Jonathan Hanhart, Catherine Schill, Christoph Hess,[...]. Nat Med 2018
452
12

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, Robert J Orlowski, Rosemarie Mick, Bertram Bengsch, Sasikanth Manne, Wei Xu, Shannon Harmon, Josephine R Giles, Brandon Wenz,[...]. Nature 2017
856
12

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski. Nature 2015
12

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.
Fei Zhao, Christine Xiao, Kathy S Evans, Tbalamayooran Theivanthiran, Nicholas DeVito, Alisha Holtzhausen, Juan Liu, Xiaojing Liu, David Boczkowski, Smita Nair,[...]. Immunity 2018
106
12

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.
Shigeki Chiba, Muhammad Baghdadi, Hisaya Akiba, Hironori Yoshiyama, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Yoichiro Fujioka, Yusuke Ohba, Jacob V Gorman, John D Colgan,[...]. Nat Immunol 2012
485
12

A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Xi Li, Rouzheng Wang, Peiwen Fan, Xuan Yao, Ling Qin, Yanchun Peng, Miaomiao Ma, Neil Asley, Xuimei Chang, Yaning Feng,[...]. Front Oncol 2019
35
12

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.
Chiara Camisaschi, Chiara Casati, Francesca Rini, Michela Perego, Annamaria De Filippo, Frédéric Triebel, Giorgio Parmiani, Filiberto Belli, Licia Rivoltini, Chiara Castelli. J Immunol 2010
196
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.